Best Insurance Stocks To Own For 2019

Amarillo National Bank raised its position in iShares S&P 500 Value ETF (NYSEARCA:IVE) by 5.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 123,840 shares of the company’s stock after buying an additional 6,639 shares during the quarter. iShares S&P 500 Value ETF comprises about 6.7% of Amarillo National Bank’s portfolio, making the stock its 4th largest holding. Amarillo National Bank’s holdings in iShares S&P 500 Value ETF were worth $14,346,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Northern Trust Corp grew its holdings in shares of iShares S&P 500 Value ETF by 12.9% during the 1st quarter. Northern Trust Corp now owns 58,230 shares of the company’s stock valued at $6,367,000 after purchasing an additional 6,650 shares during the last quarter. Blair William & Co. IL grew its holdings in shares of iShares S&P 500 Value ETF by 5.6% during the 1st quarter. Blair William & Co. IL now owns 15,855 shares of the company’s stock valued at $1,734,000 after purchasing an additional 834 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of iShares S&P 500 Value ETF by 22.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 154,815 shares of the company’s stock valued at $16,928,000 after purchasing an additional 28,085 shares during the last quarter. Ancora Advisors LLC bought a new stake in shares of iShares S&P 500 Value ETF during the 1st quarter valued at approximately $244,000. Finally, Jane Street Group LLC grew its holdings in shares of iShares S&P 500 Value ETF by 140.7% during the 1st quarter. Jane Street Group LLC now owns 2,358 shares of the company’s stock valued at $258,000 after purchasing an additional 8,153 shares during the last quarter.

Best Insurance Stocks To Own For 2019: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By George Budwell]

    Shares of the B-cell malignancy and autoimmune disease specialist TG Therapeutics (NASDAQ:TGTX) fell by an eye-popping 55.9% last month, according to data from S&P Global Market Intelligence. What triggered this dramatic sell-off?

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on TG Therapeutics Inc common stock (TGTX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Insurance Stocks To Own For 2019: Endocyte, Inc.(ECYT)

Advisors’ Opinion:

  • [By Cory Renauer]

    If these high-flying drugmakers are going to continue their climb, they have to cross some well-defined hurdles in front of them. Here’s a look at what’s ahead.

    Company (Symbol) 1-Year Gain Recent Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 535% $1.8 billion
    Viking Therapeutics, Inc. (NASDAQ:VKTX) 880% $725 million
    Endocyte, Inc. (NASDAQ:ECYT) 1,140% $1.2 billion

    Data source: Yahoo! Finance.

  • [By ]

    Exploding biotech names are nothing new to this bull market. You might recall the headline swirling around Endocyte Inc. (NASDAQ:ECYT) as it posted one-day gains of more than 150% during the fourth quarter. The triple-digit move was sparked by a licensing agreement for the firm’s phase 3 prostate cancer drug. Now, these moves are becoming almost commonplace.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Endocyte (ECYT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Endocyte, Inc. (NASDAQ:ECYT) gapped up prior to trading on Tuesday . The stock had previously closed at $16.70, but opened at $18.00. Endocyte shares last traded at $19.49, with a volume of 145358 shares changing hands.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Endocyte (ECYT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    Shares of Innovate Biopharmaceuticals (NASDAQ:INNT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), and Endocyte (NASDAQ:ECYT) have more than tripled in the first six months of 2018. What caused these biotech stocks to skyrocket — and are they still buys now?  

Best Insurance Stocks To Own For 2019: VOC Energy Trust(VOC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Deutsche Bank AG reduced its position in VOC Energy Trust (NYSE:VOC) by 64.5% in the 4th quarter, Holdings Channel reports. The firm owned 19,000 shares of the oil and gas producer’s stock after selling 34,500 shares during the period. Deutsche Bank AG’s holdings in VOC Energy Trust were worth $112,000 as of its most recent filing with the SEC.

Leave a Reply

Your email address will not be published. Required fields are marked *